Claim Your Discounted Prosta Peak
Below While Stock Lasts!

STARTER

60 Day Supply (2 Bottles)

$79Per Bottle

+ Shipping

TOTAL: $790 $158

BEST VALUE

180 Day Supply (6 Bottles)

$49Per Bottle

+ Free Shipping

+ 2 free Bonuses

TOTAL: $1176 $294

MOST POPULAR

90 Day Supply (3 Bottles)

$69Per Bottle

+ Free Shipping

+ 2 free Bonuses

TOTAL: $828 $207

MOST POPULAR

90 Day Supply (3 Bottles)

$69Per Bottle

+ Free Shipping

+ 2 free Bonuses

TOTAL: $828 $207

BEST VALUE

180 Day Supply (6 Bottles)

$49Per Bottle

+ Free Shipping

+ 2 free Bonuses

TOTAL: $1176 $294

STARTER

60 Day Supply (2 Bottles)

$79Per Bottle

+ Shipping

TOTAL: $790 $158

Our customers say

100% Satisfaction
180-Day Money Back Guarantee

Your order today is covered by our iron-clad 180-day 100%
money-back guarantee. If you are not impressed by the transformation in your Prostate health, then at any time in the next 180 days write to us and we’ll refund every single cent.

Claim Your Discounted Prosta Peak
Below While Stock Lasts!

STARTER

60 Day Supply (2 Bottles)

$79Per Bottle

+ Shipping

TOTAL: $790 $158

BEST VALUE

180 Day Supply (6 Bottles)

$49Per Bottle

+ Free Shipping

+ 2 free Bonuses

TOTAL: $1176 $294

MOST POPULAR

90 Day Supply (3 Bottles)

$69Per Bottle

+ Free Shipping

+ 2 free Bonuses

TOTAL: $828 $207

MOST POPULAR

90 Day Supply (3 Bottles)

$69Per Bottle

+ Free Shipping

+ 2 free Bonuses

TOTAL: $828 $207

BEST VALUE

180 Day Supply (6 Bottles)

$49Per Bottle

+ Free Shipping

+ 2 free Bonuses

TOTAL: $1176 $294

STARTER

60 Day Supply (2 Bottles)

$79Per Bottle

+ Shipping

TOTAL: $790 $158

Our customers say

Manufactured in the USA from the finest of foreign and domestic ingredients.

Scientific References:

  1. Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7 Suppl 9(Suppl 9):S3-S14.
  2. Abrams P. LUTS, BPH, BPE, BPO: A Plea for the Logical Use of Correct Terms. Rev Urol. 1999 Spring;1(2):65.
  3. Silverman WM. "Alphabet soup" and the prostate: LUTS, BPH, BPE, and BOO. J Am Osteopath Assoc. 2004 Feb;104(2 Suppl 2):S1-4.
  4. Abrams P. New words for old: lower urinary tract symptoms for "prostatism". BMJ. 1994 Apr 09;308(6934):929-30.
  5. Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S11-8.
  6. Parsons JK. Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors. Curr Bladder Dysfunct Rep. 2010 Dec;5(4):212-218.
  7. Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, Te AE, Kaplan SA. Benign prostatic hyperplasia. Nat Rev Dis Primers. 2016 May 05;2:16031.
  8. Schenk JM, Calip GS, Tangen CM, Goodman P, Parsons JK, Thompson IM, Kristal AR. Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2012 Jul 15;176(2):156-63.
  1. Sutcliffe S, Grubb Iii RL, Platz EA, Ragard LR, Riley TL, Kazin SS, Hayes RB, Hsing AW, Andriole GL., Urologic Diseases in America Project. Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. BJU Int. 2012 Oct;110(7):1050-9.
  2. Nygård LH, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ. The effect of non-steroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia. Prostate. 2017 Jun;77(9):1029-1035.
  3. Kukko V, Kaipia A, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ. Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort. Prostate Cancer Prostatic Dis. 2018 Sep;21(3):373-378.
  4. Foster CS. Pathology of benign prostatic hyperplasia. Prostate Suppl. 2000;9:4-14.
  5. Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate. 1984;5(5):545-57.
  6. Gann PH, Hennekens CH, Longcope C, Verhoek-Oftedahl W, Grodstein F, Stampfer MJ. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate. 1995 Jan;26(1):40-9.
  7. Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond). 2005 Mar;29(3):310-6.
  8. Nygård LH, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ. Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia. Prostate. 2023 Feb;83(3):246-258.